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doi:10.1016/j.ejvs.2008.06.034Abstract Objective: The aim of the present study was to analyze our results of treating
synthetic vascular graft infection in the aorto-femoral segment with venous allografts.
Patients and methods: During 1997e2006 we treated 11 male patients with venous allografts
for aorto-femoral segment prosthetic graft infection. Patients were followed postoperatively
with patency assessment based on Doppler ultrasonography.
Results: The mean interval between the implantation of the synthetic vascular graft and the
appearance of infection was 43  29 months (range 5 monthse10 years). Overall primary
patency of the venous allograft was 100%, 88% and 66% at 1, 6 and 36 months, respectively.
Secondary patency rates of the venous allograft were 94% and 73% after 5 and 8 years, respec-
tively. Overall survival rate was 100%, 64%, 46% and 27% after one month, 3, 5 and 8 years,
respectively. Limb salvage rate was 100%, 94% and 73% after 1 month, 5 and 8 years, respec-
tively.
Conclusions: The use of in situ venous allograft for the treatment of synthetic graft infection in
the aorto-femoral segment has led to favourable short- and long-term results.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The incidence of synthetic vascular graft infection is up to
6%.1 Synthetic vascular graft infection is one of the most
serious complications in vascular surgery, associated withik, Department of Vascular
Puusepa Street, 51014 Tartu,
um.ee (A. Aavik).
ty for Vascular Surgery. Publishea mortality up to 50%, amputation rate up to 20%2,3 and an
incidence of re-infection up to 22%.3,4 Several options have
been proposed to treat this problem including both allo-
and auto-grafts. Within recent years Rifampicin-bonded or
Silver-coated synthetic vascular grafts have been used.4,5
With Rifampicin-bonded and silver-coated vascular grafts
the incidence of reinfection was 9e11% and 3.7e6.5% while
postoperative mortality was 8e18% and 6.5e16.6%,
respectively.3e7 In addition, arterial allografts8e14 and
superficial femoral vein autografts15e17 have been used ind by Elsevier Ltd. All rights reserved.
Table 1 Original and interim operations
No. Original operation Objective before original
operation
Interim operations Period 1 Period 2
1 Aorto-bifemoral bypass Rest pain None 47 X
2 Aorto-bifemoral bypass Rest pain Distal anastomosis correction 57 1
3 Ileo-femoral bypass Post-traumatic iliac artery
pseudoaneurysma
Distal anastomosis correction 119 1
4 Ileo-femoral bypass Gangrene Femoro-popliteal bypass with
synthetic graft
33 23
Toe amputation
Refemoro-popliteal bypass with
autovein
5 Aorto-bifemoral bypass Rest pain None 14 X
6 Aorto-femoral bypass Rest pain Axillo-femoral bypass removal 5 1
7 Aorto-bifemoral bypass Rest pain None 32 X
8 Aorto-femoral bypass Ischaemic ulcer Femoro-popliteal bypass with
synthetic graft and allovein cuff
48 32
Amputation below knee
9 Aorto-bifemoral bypass Rest pain Femoro-popliteal bypass with
synthetic graft
34 34a
10 Aorto-bifemoral bypass Rest pain Distal anastomosis correction 52 2
Resection of anastomotic
aneurysm with deep femoral
artery plastic
11 Aorto-bifemoral bypass Gangrene None 37 X
Period 1 e time in months from original operation to synthetic graft infection diagnosis
Period 2 e time in months from performed last interim operation to synthetic graft infection diagnosis.
a Patient No 9 had femoro-popliteal bypass with synthetic graft 14 days after aorto-bifemoral bypass.
Table 2 Clinical presentation of all patients with infected
synthetic vascular graft
Clinical signs Number of
patients
Groin abscess 4
Purulent groin fistula 3
Intermittent
bleeding from groin fistula
2
Acute bleeding from
groin fistula with
haemorrhagic shock
2
Distal anastomosis rupture 1
Aorto-bifemoral bypass
branch occlusion with gangrene
1
Fever 7
Intermittent claudication 5
Ischemic ulcer 1
Synthetic Graft Infection 433situ at the site of infection. However, publications
regarding the use venous allografts for graft infection have
been scarce. Our department has extensive experience in
using venous allografts since 1997.18 The aim of the present
research is to analyze the results of treatment of synthetic
vascular graft infection with venous allografts.
Patients and Methods
Patients
During 1997e2006 we treated 11 male patients with venous
allografts for the treatment of aorto-femoral segment
prosthetic graft infection. During surgery we used venous
allografts removed during varicose vein surgery for in situ
revascularization. The average diameter of the harvested
veins were 8e9 mm. The average age of patients at the
time of diagnosing synthetic graft infection was 63.5 7.5
years (range 45e75 years). The indication for the primary
operation was occlusive disease in the aortoiliac segment in
ten cases and posttraumatic pseudoaneurysm of the iliac
artery in one case (Table 1).
The interval between the implantation of synthetic
vascular graft and the appearance of infection was 43 29
months (range 5 monthse10 years). Seven of the 11
patients had required further reconstructive operations
during there follow-up to treat progressive atherosclerosis.
The clinical signs of vascular synthetic graft infection of
these patients are presented in Table 2. In all cases,Doppler ultrasound and CT scan revealed a thin layer of
liquid around the synthetic graft; perigraft abscess or
collection. Digital subtraction angiography was not used
any cases.
Vein harvesting
We used great saphenous veins removed during varicose
vein surgery using a flexible intraluminal phleboextractor.
Table 3 Operations performed
Operation No.
Aorto-bifemoral bypass 6
Aorto-femoral bypass 3
Ilio-femoral bypass 2
434 A. Aavik et al.Our previous experience has demonstrated that only the
femoral part of great saphenous vein is useful for recon-
struction of the aorta. The accepted average diameter
were 8e9 mm. We avoid the use of areas with varicosities
and clear inflammation changes. In two cases we over-
sewed local varicosities of 1 cm in length. In more severe
varicosities we resected and re-anastomosed the vein
segment. Either tube or aorto-bifemoral grafts were
produced from the good quality venous segments. In 6 cases
we combined different veins for allograft construction (all
aorto-bifemoral cases). Venous allografts were preserved in
isotonic saline (0.9% NaCl), which also contained heparin
and ampicillin, at 4 C for up to 15 days.
All donors had been tested for hepatitis B and C as well
as for HIV types 1 and 2. ABO/Rh system compatibility was
not attempted in any of the cases. Ethical approval and
informed consent were obtained from donors and recipi-
ents for venous allografting and HIV testing.Surgical procedures
Two patients required emergency surgical treatment for
bleeding from groin fistulae. Elective surgery was per-
formed in nine patients.
In all cases the circulation to lower extremities was
restored in situ using venous allografts that had been
removed during varicose vein surgery. The venous allografts
was prepared on the previous day or immediately before
surgery. In all cases distal anastomoses of the synthetic
transplant were first dissected in the groin. Total laparotomy
was then performed and the proximal anastomosis of the
synthetic vascular graft was found. In aorto-bifemoral or
aorto-femoral bypasses the aorta was clamped at the left
renal vein and distal flow was blocked using a balloon
occlusion catheter. In the ilio-femoral bypass cases the
common iliac arterywas clampednear the aortic bifurgation.
In all cases retrogradeflow fromdeep femoral and superficial
femoral arteries were controlled with balloon occlusion
catheters.
The infected synthetic vascular graft was next removed.
The proximal anastomosis of a new allotransplant (aorto-
bifemoral, aorto-femoral or ilio-femoral bypass) was
established at the site of the proximal anastomosis of the
previous synthetic vascular graft and the distal anasto-
moses were performed to the femoral arteries. During
surgery samples were examined microscopically to guide
the extent of the graft infection. As far as possible,
debridement was performed to normal tissues and the
compartment of infected synthetic vascular graft was
rinsed with polyvinoliodide solution. Vacuum drains were
left in the region of all anastomoses. Drains were removed
when less than 10 ml was discharged within 24 hours.
Continuous suture with 3/0e4/0 polypropylene was used
for all anastomoses. Heparin 40 IU/kg was administered
intraoperatively. Post-operatively no anticoagulants or
immunosuppressants were used (Table 3).
All patients received intravenous antibiotics for a mean
of 8 2 days (range 5e12 days) after surgery. If the caus-
ative agent of the synthetic vascular graft infection was
known preoperatively, antibiotic treatment was prescribed
according to sensitivities (3 cases). In emergency situations(2 cases) the initial empiric antibacterial treatment was
prescribed according to microscopy findings. Preoperative
antibacterial treatment was not prescribed to patients (3
cases) who did not have fever, leukocytosis and increased
CRP. In three cases in which the infective agent was
unknown preoperative antibacterial treatment with second
and third generation cephalosporins was commenced,
because the patients presented the clinical signs of septic
shock. The duration of preoperative antibacterial treat-
ment was four days on average. The indicators for stopping
postoperative antibiotic therapy were the normalization of
temperature, leukocytosis and CRP.
All patients were subject to regular follow-up at inter-
vals of 6 months which included clinical examination and
Doppler ultrasound. A graft was considered patent if
Doppler ultrasound confirmed patency.
Statistical analysis
Clinical information was tabulated for all patients. Life-
table method was used to calculate primary patency and
limb salvage rates.
Results
Bacteriology
Cultures for bacteriological testing were collected preop-
eratively from three patients with purulent groin fistulae,
from two patients with a history of bleeding from groin
fistulae and from three patients with groin abscesses.
Intraoperatively cultures for bacteriological testing were
taken from the infected graft and surrounding tissue during
all 11 operations.
Microbiological culture was positive in 3 out of 8 patients
(38%) preoperatively and in 6 out of 11 patients post-
operatively (55%). Staphylococci were most commonly iso-
lated (4 cases out of 11, 36%) but MRSA was not present in
any of the cases. Fungi were isolated in none of the cases.
In 46% of the cases classical microbial cultures failed to
identify a pathogen (Fig. 1).
Early (up to 30 days) results
The mean duration of follow-up was 59 37 (range 13e102)
months. None of the patients died during the early post-
operative period. One patient required ventilation for one
day during the immediate postoperative period. During the
postoperative period, there were no cases of bleeding in
the region of anastomoses and no wound complications.
One patient needed trans-femoral amputation due to
gangrene of the lower extremity 12 days prior to the
36%
9%9%
46%
Staphylococcus spp. Streptococcus spp.
Pseudomonas spp. No microbs detected
Figure 1 Microorganisms grown from infected prosthetic
graft postoperatively.
Synthetic Graft Infection 435removal of infected prosthetic graft. It was not possible to
perform the abovementioned operation in one stage due to
the serious general condition of the patient (septic shock).
The mean duration of postoperative hospitalization after in
situ revascularization with venous allograft was 14 4 days
(range 7e19 days).
Late results
Eight of the eleven patients died during the follow-up
period. The cause of deaths were unrelated to the venous
allografts. One patient commit suicide 1.3 years later. One
patient died 4.3 years later due to metastatic cancer. Two
patients died secondary to myocardial infarction 1.6 and
3.1 years later. Four patients died due to progressive
chronic cardiovascular disease 1.1, 2.6, 8.7 and 8.8 years
later.
Trans-femoral amputation was performed in one patient
six months after allograft implantation due to thrombosis of
aorto-bifemoral bypass branch and peripheral thrombosis
as a result of haemoconcentration and distal junction
stenosis. At the same stage angioplasty of the distal anas-
tomosis of the contralateral branch with patch was per-
formed for a stenosis.
One patient was hospitalized 40 months after aorto-
bifemoral bypass implantation due to the occlusion of one
limb of aorto-bifemoral bypass and acute ischemia caused
by thromboembolism from left atrium. Successful throm-
bectomy was performed, but ischemic damage of peroneal
nerve persisted.Figure 2 A. Primary patency rates for 11 patients (17 legs) with
numbers above the curve indicate grafts at risk. B. Limb salvage rate
with venous allografts.One patient required additional femoro-popliteal bypass
with a venous allograft six months after ileo-femoral
grafting due to progression of occlusive disease. The
following surgical procedures were performed in one
patient in addition to the aorto-bifemoral venous allograft:
femoro-popliteal bypass one month later; thrombectomy
from the right limb of aorto-bifemoral bypass 29 months
later, thrombectomy from the left limb of aorto-bifemoral
bypass along with deep femoral arterioplasty 32 months
later and again thrombectomy from the left limb of aorto-
bifemoral bypass along with additional femoro-popliteal
bypass 62 months later. All these additional surgical
procedures were required because of very rapid progression
of peripheral arterial disease.
The primary cumulative patency of the venous allografts
were 100%, 88%, 66.3% and 55.2% after one month, six
months, three years and eight years, respectively (Fig. 2A).
Secondary patency rates were 94.1% and 73.2% at 1 and 8
years, respectively. Overall survival rate was 100%, 63.6%,
45.5% and 27.3% after one month, 3, 5 and 8 years,
respectively. Limb salvage rates were 100%, 94% and 73%
after one month, 5 years and 8 years, respectively (Fig. 2B).
Discussion
The early postoperative (up to 30 days) and 10 years follow-
up results of our study reflect the safety and efficacy of
venous allografts in the treatment of synthetic graft
infection in the aorto-femoral segment. The incidence of
amputation following synthetic vascular graft infection
treated during the whole period was 5.9%. This is compa-
rable in with similar studies previously published (Table 4).
In the present study the causative agent of synthetic
vascular graft infection remained unverified in 45% of the
cases. We would like to point out two significant factors:
Preoperative antibacterial treatment and biofilm-forming
microbes with low virulence that conventional microbio-
logical methods fail to culture.
Our department has extensive and positive experience in
using venous allografts removed during varicose vein
surgery since 1978,18 however, we lack experience using
Rifampicin-bonded and Silver-coated grafts.
Davies and Parums claimed that from the morphological
aspect the best medium for preserving allografts is saline at
4 C, as the basal membrane and collagen matrix aresynthetic graft infection treated with venous allografts. The
s for 11 patients (17 legs) with synthetic graft infection treated
Figure 3 Left side venous allograft ilio-femoral bypass after
8 years, proximal anastomosis end to end, distal anastomosis
end to side (CT-angiography).
Table 4 Other cases series
Author Year No. of
patients
Mean follow-up
(mo)
Operative
mortality (%)
Amputation
(%)
Secondary
infection (%)
Conventional treatment
Yeager et al.23 1999 60 41 13 10 10
Bandyk et al.22 2001 31 26 21 9 3
Autogenous vein
Nevelsteen et al.16 1995 15 17 7 7 0
Bandyk et al.22 2001 10 26 10 10 3
Daenens et al.15 2003 49 41 8 2 0
Allografts
Nevelsteen et al.14 1998 30 24.5 11 6.7 6.7
Verhelst et al.8 2000 90 36 17 1 1
Leseche et al.9 2001 28 35.4 17.8 0 0
Vogt et al.10 2002 49 27 6 0 2
Noel et al.11 2002 56 5.3 13 5 4
Current study 2008 11 59 0 5.9 0
Antibiotic bonded
prosthesis
Hayes et al.4 1999 11 e 18 0 9
Young et al.3 1999 9 36 8 0 11
Bandyk et al.22 2001 16 18 0 0 10
IGS* prosthesis
Zegelman & Gunther7 2002 44 11 6.5 e 6.5
Batt et al.5 2003 27 17 16.6 0 3.7
436 A. Aavik et al.maintained.19 Another advantage of preservation in saline
at 4 C over other techniques is rapid disappearance of
endothelial cells. This limits rejection reactions that can
lead to occlusion.19 Preserving allografts at 4 C causes
exfoliation of the endothelial cells and reduces the amount
smooth muscle cells in the medium.20 The low incidence of
graft rejection using venous allografts may be due to the
lack of HLA-II antigen expression in the wall of large
vessels. The rejection process involves cell-mediated
immunity to venous allografts and is not eliminated with
low-dose azathioprine. There is also indirect evidence of
participation of humoral immunity in venous allograft
rejection.21 None of the venous allografts we used were
matched for ABO or HLA antigens, however, we did not find
evidence of graft rejection. The graft patency rate was 77%
after 8 years.
We had no re-infection in the study group. Allografts
may have more intensive antimicrobial activity compared
to synthetic grafts, because they are preserved in antibiotic
solutions and for example, in the research of Vogt et al. and
Teebken et al. antibiotic-containing fibrin adhesive was
used to cover allograft anastomoses.10,13
In situ reconstruction with autologous superficial
femoral vein has so far been the most effective way for
preventing re-infection, but this type of surgery is prob-
lematic in emergency situations due to the additional
amount of time required.14,16,22 Also, this type of surgery is
contraindicated in the case of previous deep vein throm-
bosis and up to 12% of patients may develop postoperative
compartment syndrome.17
Yeager et al. reported that extraanatomical recon-
struction is associated with >25% rate of secondarycomplications.23 In addition, there is a significant incidence
of re-infection (3e10%).22,23
Based on our small series the use of allografts formed
from varictomized alloveins in situ for the treatment of
synthetic graft infection in the aorto-femoral segment has
Figure 4 Aorto-bifemoral venous allograft after 6 years, all
anastomoses end to side (CT-angiography).
Synthetic Graft Infection 437favourable short- and long-term results and is an alterna-
tive to other methods currently used (Figs. 3 and 4).Acknowledgement
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